Sandoz launches the first generic version of Hectorol®

Princeton, New Jersey, February 5, 2014 – Sandoz today announced the US launch of doxercalciferol injection vials, the first generic version of Genzyme’s Hectorol®.

Doxercalciferol injection vials are indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.1

“Sandoz is pleased to be the first company to market a high quality, affordable generic version of this important product to dialysis patients in the US,” said Peter Goldschmidt, President of Sandoz Inc.

Sandoz is marketing …

/by

Sandoz recognizes World Cancer Day 2014

February 4, 2014 – Today Sandoz recognizes World Cancer Day. Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths (around 13% of all deaths) in 2008, according to the World Health Organization. Deaths from cancer worldwide are projected to continue rising, with an estimated 13.1 million deaths in 2030.

The high cost of treating cancer can be a significant barrier to patients. Well over half of all cancer deaths (70%) in 2008 occurred in low- and middle-income countries, according to the World Health Organization. Sandoz oncology injectables …

/by

Bulgaria approves Sandoz’s Airflusal® Forspiro®

Holzkirchen, Germany, February 4, 2014 – Sandoz announced today it has received Bulgarian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

In January, 2014 Sandoz also received marketing authorizations for AirFluSal® Forspiro® in Germany, Sweden, Hungary and …

/by